Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2024-04-01 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于首次回购公司股份暨回购股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about its first share repurchase and the progress of the share buyback plan. It details the number of shares repurchased, prices, total amount spent, and compliance with regulatory guidelines. The text references a specific share repurchase plan approved at a shareholders meeting and provides updates on the repurchase activity. There are no financial statements or comprehensive financial data presented, only information about the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buying back its own shares.
2024-04-01 Chinese
关于公司完成工商变更登记并换发营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about completing a business registration change and obtaining a new business license. It includes details about the company's registration capital, legal representative, business scope, and other registration information. There is no financial data, no mention of financial results, no meeting materials, no voting results, no legal proceedings, no executive changes, and no report attachments. The document is a regulatory announcement about corporate registration changes, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories.
2024-03-11 Chinese
关于回购股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from a company regarding the progress of its share repurchase program. It details the approval of a share buyback plan, the intended use of funds, the price limits, and the reporting obligations under stock exchange regulations. It explicitly states that as of the date, no shares have been repurchased yet and that the company will continue to disclose updates as required. The document is short (670 characters) and focuses on the status of a share repurchase, which fits the category of a Transaction in Own Shares (POS) filing. It is not a full financial report, earnings release, or regulatory certification, but a progress update on share buybacks.
2024-03-04 Chinese
2024年第一次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and compliance of the convening, holding, attendance, and voting procedures of the 2024 first extraordinary general meeting (临时股东大会) of Xiamen Aide Biomedical Technology Co., Ltd. It details the meeting's notice, attendance, voting results, and legal compliance with relevant laws and company articles. The document is not a financial report, earnings release, or management discussion. It is a legal opinion related to a shareholders' meeting and the voting results of proposals, including share repurchase and capital change. This type of document corresponds to a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of a shareholders' meeting. The document length is over 5,000 characters and contains detailed voting results and legal opinions, not just an announcement of a report publication or a brief notice. Therefore, the correct classification is DVA with high confidence.
2024-02-26 Chinese
关于回购股份用于注销并减少注册资本暨通知债权人的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement by Xiamen Aide Biomedical Technology Co., Ltd. regarding the company's share repurchase plan to cancel shares and reduce registered capital. It includes details about the repurchase amount, price limits, implementation period, and a notification to creditors about their rights to claim debts within 45 days. The document is an official notice about a share buyback and capital reduction, not a financial report or earnings release. It does not contain financial statements or detailed financial data but rather informs stakeholders about the share repurchase and related creditor notification. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is short (1269 characters), and it is not merely an announcement of a report but the actual notice of the share repurchase plan and creditor notification.
2024-02-26 Chinese
回购报告书
Transaction in Own Shares Classification · 100% confidence The document is titled '回购报告书' which translates to 'Repurchase Report' or 'Buyback Report'. It details a share repurchase plan including the type of shares to be repurchased, the purpose (to cancel and reduce registered capital), price range, implementation period, funding source, and expected number of shares to be repurchased. It also includes risk disclosures, management analysis on the impact of the repurchase, and authorizations for the repurchase. The document is comprehensive and contains substantive financial data and operational details about the share repurchase program. This matches the definition of a 'Transaction in Own Shares' filing, which reports on the company's buyback of its own shares. The document is not a brief announcement or a regulatory filing, but a detailed report on the share repurchase plan and related information.
2024-02-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.